B
Brandon Dale
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 5
Citations - 333
Brandon Dale is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Medicine & PRC2. The author has an hindex of 2, co-authored 2 publications receiving 69 citations.
Papers
More filters
Journal ArticleDOI
Advancing targeted protein degradation for cancer therapy.
TL;DR: In this paper, the molecular basis of targeted protein degradation is discussed and a comprehensive review of the most promising degraders in development as cancer therapies to date is provided, with a focus on opportunities and challenges for future development.
Journal ArticleDOI
Discovery of a first-in-class EZH2 selective degrader.
Anqi Ma,Elias E. Stratikopoulos,Kwang-Su Park,Jieli Wei,Tiphaine Martin,Xiaobao Yang,Megan C. Schwarz,Violetta V. Leshchenko,Alexander Rialdi,Brandon Dale,Alessandro Laganà,Ernesto Guccione,Samir Parekh,Ramon Parsons,Jian Jin +14 more
TL;DR: MS1943 has a profound cytotoxic effect in multiple TNBC cells, while sparing normal cells, and is efficacious in vivo, suggesting that pharmacologic degradation of EZH2 can be advantageous for treating the cancers that are dependent on EZh2.
Journal ArticleDOI
Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies.
Xufen Yu,Jia Xu,Yu-Ming Shen,Kaitlyn M. Cahuzac,Kwang-Su Park,Brandon Dale,Jing Liu,Ramon Parsons,Jian Jin +8 more
TL;DR: SAR studies that led to the discovery of MS21 are presented, another VHL-recruiting AKT degrader, MS143 (compound 20) with similar potency as MS21, and a novel cereblon (CRBN)- Recruiting PROTAC, MS5033 (compounds 35).
Journal ArticleDOI
Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2.
Brandon Dale,Chris Anderson,Kwang-Su Park,H. Ümit Kaniskan,Anqi Ma,Yu-Ming Shen,Chengwei Zhang,Ling-Li Xie,Xin Chen,Xufen Yu,Jian Jin +10 more
TL;DR: A novel, potent, and selective EZH2 PROTAC degrader is reported, MS8815 (compound 16), which induced robust EZh2 degradation in a concentration-, time- and proteasome-dependent manner in TNBC cells, and effectively suppressed the cell growth.
Journal ArticleDOI
Targeted Degradation of PRC1 Components, BMI1 and RING1B, via a Novel Protein Complex Degrader Strategy
Kwang-Su Park,Lihuai Qin,M H Kabir,Kaixiu Luo,Brandon Dale,Yue Zhong,Arum Kim,Gang Wang,H. Ümit Kaniskan,Jian Jin +9 more
TL;DR: MS147 as mentioned in this paper is a protein complex degradation strategy that utilizes the target protein's interacting partner protein (EED) to degrade BMI1 and RING1B in an EED-, VHL-, ubiquitination and time-dependent manner.